Future novel therapeutic agents forClostridium difficileinfection

In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas

(2010) Z-D Jiang et al.   JOURNAL OF CLINICAL PATHOLOGY

Clostridium difficile— Beyond Antibiotics

(2010) Lorraine Kyne   NEW ENGLAND JOURNAL OF MEDICINE

Treatment with Monoclonal Antibodies againstClostridium difficileToxins

(2010) Israel Lowy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection

(2009) D.M. Citron et al.   ANAEROBE

Intravenous Tigecycline as Adjunctive or Alternative Therapy for Severe RefractoryClostridium difficileInfection

(2009) Bjorn L. Herpers et al.   CLINICAL INFECTIOUS DISEASES

Nitazoxanide versus Vancomycin inClostridium difficileInfection: A Randomized, Double‐Blind Study

(2009) Daniel M. Musher et al.   CLINICAL INFECTIOUS DISEASES

High Frequency of Rifampin Resistance Identified in an EpidemicClostridium difficileClone from a Large Teaching Hospital

(2009) Scott R. Curry et al.   CLINICAL INFECTIOUS DISEASES

Activity of tigecycline against recent European clinical isolates of Clostridium difficile

(2009) Stephen P. Hawser   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Clostridium difficile ribotypes 027 and 106: clinical outcomes and risk factors

(2009) F. Sundram et al.   JOURNAL OF HOSPITAL INFECTION

Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI)

(2009) Brett A. Leav et al.   VACCINE

Study of the In Vitro Activities of Rifaximin and Comparator Agents against 536 Anaerobic Intestinal Bacteria from the Perspective of Potential Utility in Pathology Involving Bowel Flora

(2008) S. M. Finegold et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rifampin and Rifaximin Resistance in Clinical Isolates of Clostridium difficile

(2008) J. R. O'Connor et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of OPT-80 Tested against Clinical Isolates of Toxin-Producing Clostridium difficile

(2008) J. A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a Phase 2 Trial with Patients with Clostridium difficile Infection

(2008) T. Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile Infection

(2008) T. J. Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Treatment ofClostridium difficileInfection

(2008) Dale N. Gerding et al.   CLINICAL INFECTIOUS DISEASES

Measures to Control and PreventClostridium difficileInfection

(2008) Dale N. Gerding et al.   CLINICAL INFECTIOUS DISEASES

Executive Summary: Scientific and Regulatory Challenges of Development of Probiotics as Foods and Drugs

(2008) Freddie Ann Hoffman et al.   CLINICAL INFECTIOUS DISEASES

Rifaximin in Treatment of Recurrent Clostridium difficile-associated Diarrhea: An Uncontrolled Pilot Study

(2008) Kevin W. Garey et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A

(2008) Claribel P. Taylor et al.   VACCINE

Saccharomyces boulardii ameliorates Citrobacter rodentium-induced colitis through actions on bacterial virulence factors

(2007) X. Wu et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY